E2F6P4

Across TCGA pan-cancer cohorts, E2F6P4 RNA is linked to patient survival in 16 of 34 cancer types, making it the most broadly survival-associated E2F6P4 data layer.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher E2F6P4 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated E2F6P4 expression acts as an unfavorable survival marker, although some lineages such as UCS and LAML show a favorable association.

LUAD, STAD, and ACC are the cancer types where E2F6P4 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Tertile	All	0.559	0.711	<.001	81	view →
STAD	DFS	Tertile	IV	0.181	0.661	.004	49	view →
ACC	DFS	Tertile	III,IV	0.046	0.670	.001	45	view →
DLBC	OS	Tertile	III,IV	0.172	0.907	<.001	36	view →
UCS	OS	Tertile	III,IV	0.564	0.220	.036	24	view →
LAML	DFS	Median	All	0.658	0.325	.005	20	view →
CESC	DFS	Quartile	II,III,IV	0.272	0.615	.020	14	view →
KIRC	DFS	Tertile	All	0.521	0.652	.024	12	view →
SKCM	OS	Tertile	IV	0.226	0.613	.034	9	view →
LGG	OS	Tertile	All	0.973	0.878	.002	6	view →
LIHC	OS	Tertile	III,IV	0.441	0.655	.025	6	view →
PRAD	OS	Tertile	All	0.975	0.995	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 16 lineages.

E2F6P4–LUAD (OS)

Open the LUAD breakdown →